The Alignment of Innovation Policy and Social Welfare: Evidence from Pharmaceuticals

Margaret K. Kyle

Chapter in NBER book Innovation Policy and the Economy, Volume 20 (2020), Josh Lerner and Scott Stern, editors (p. 95 - 123)
Conference held April 16, 2019
Published in December 2019 by University of Chicago Press
© 2020 by the National Bureau of Economic Research
in NBER Book Series Innovation Policy and the Economy

This chapter provides an overview of different innovation policies and their performance in the pharmaceutical sector. I emphasize three points. First, both push and pull policies have generally promoted pharmaceutical research for diseases with large burdens. Second, imperfections in product and capital markets undermine the efficiency of pull policies. Similarly, the allocation of public funds is not always optimal, which limits the efficacy of push policies. Finally, the need to coordinate or adapt to policies choices in other countries is often overlooked in both economic studies of pharmaceutical R&D as well as policy choices.

You may be able to access the full text of this document via the Document Object Identifier.

Acknowledgments

Machine-readable bibliographic record - MARC, RIS, BibTeX

Document Object Identifier (DOI): 10.1086/705640